← Back to Search

Vitamin

Vitamin C for Sepsis

Phase 2
Waitlist Available
Led By Michael D Sharpe, MD FRCPC
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days or discharge from intensive care unit
Awards & highlights

Study Summary

This study is designed to determine if Vitamin C administration to septic patients will result in an improvement in organ dysfunction which occurs during a septic illness. Hypothesis: 1. Vitamin C in sepsis will reduce the injury to organs 2. Vitamin C will reduce the length of time on a ventilator, length of stay in the intensive care unit and in hospital.

Eligible Conditions
  • Sepsis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days or discharge from intensive care unit
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days or discharge from intensive care unit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sequential organ function assessment score (SOFA)
Secondary outcome measures
Biomarkers as a measure of coagulation, inflammation and oxidative stress.

Side effects data

From 2023 Phase 2 trial • 61 Patients • NCT03146962
29%
Abdominal pain
29%
Fatigue
29%
Alkaline phosphatase increased
14%
Alanine aminotransferase increased
14%
Blood bilirubin increased
14%
Nausea
14%
Peripheral Sensory Neuropathy
14%
Other: Blood in Stool
14%
Edema Limbs
14%
Other: Neuropathy, Type Unspecified
14%
Vomiting
14%
Other: Increased Lactate Dehydrogenase
14%
Generalized Muscle Weakness
14%
Other: COVID-19 Infection
14%
Flu Like Symptoms
14%
Upper Respiratory Infection
14%
Anal Hemorrhage
14%
Other: Cold Intolerance
14%
Constipation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort A: Vitamin C + Surgery
Cohort C: Vitamin C + Y-90 Dose Level 1
Cohort C: Vitamin C + Y-90 Dose Level 7
Cohort C: Vitamin C + Y-90 Dose Level 4
Cohort C: Vitamin C + Y-90 Dose Level 8
Cohort C: Vitamin C + Y-90 Dose Level 2
Cohort C: Vitamin C + Y-90 Dose Level 6
Cohort B Vitamin C Only
Cohort C: Vitamin C + Y-90 Dose Level 3
Cohort C: Vitamin C + Y-90 Dose Level 5

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Vitamin CExperimental Treatment1 Intervention
Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
Group II: placeboPlacebo Group1 Intervention
placebo vehicle administered in same fashion as active treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ascorbic acid
FDA approved

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
661 Previous Clinical Trials
413,902 Total Patients Enrolled
5 Trials studying Sepsis
1,750 Patients Enrolled for Sepsis
Michael D Sharpe, MD FRCPCPrincipal InvestigatorLondon Health Sciences Centre
2 Previous Clinical Trials
54 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Outcome Following Vitamin C Administration in Sepsis
Michael Sharpe 2012. "Outcome Following Vitamin C Administration in Sepsis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01590303.
All > Sepsis
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top